Emergent BioSolutions (NYSE:EBS) Downgraded by StockNews.com to Hold

StockNews.com downgraded shares of Emergent BioSolutions (NYSE:EBS) from a buy rating to a hold rating in a research note published on Wednesday morning.

EBS has been the topic of a number of other research reports. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Emergent BioSolutions in a research note on Tuesday. Benchmark upped their price target on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th.

Emergent BioSolutions Trading Down 9.3 %

Shares of Emergent BioSolutions stock opened at $5.80 on Wednesday. Emergent BioSolutions has a 12-month low of $1.82 and a 12-month high of $15.10. The stock has a market capitalization of $314.00 million, a P/E ratio of -1.41 and a beta of 1.62. The company has a 50-day simple moving average of $9.43 and a 200 day simple moving average of $9.02. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30.

Emergent BioSolutions (NYSE:EBS) last posted its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.40. The company had revenue of $194.70 million during the quarter, compared to analyst estimates of $254.67 million. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. During the same quarter last year, the business posted ($0.77) earnings per share. Research analysts expect that Emergent BioSolutions will post -0.63 earnings per share for the current fiscal year.

Institutional Trading of Emergent BioSolutions

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Entropy Technologies LP bought a new position in shares of Emergent BioSolutions in the 3rd quarter valued at about $155,000. Landscape Capital Management L.L.C. bought a new position in Emergent BioSolutions in the third quarter valued at approximately $141,000. FMR LLC boosted its stake in Emergent BioSolutions by 12.6% in the third quarter. FMR LLC now owns 129,099 shares of the biopharmaceutical company’s stock valued at $1,078,000 after acquiring an additional 14,446 shares during the last quarter. FORA Capital LLC acquired a new stake in Emergent BioSolutions during the 3rd quarter worth $103,000. Finally, Hilltop Holdings Inc. raised its position in shares of Emergent BioSolutions by 7.9% during the 3rd quarter. Hilltop Holdings Inc. now owns 171,266 shares of the biopharmaceutical company’s stock valued at $1,430,000 after acquiring an additional 12,515 shares during the last quarter. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.